Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Dolutegavir access in the Asia-Pacific region

This factsheet provides information on the use of dolutegravir in HIV treatment and access to dolutegravir under Medicines Patent Pool voluntaray licenses.

Published
27 June 2017
From
amfAR Treat Asia
Last Gift Study: Community Perspective on End-of-Life HIV Research

In the second of this 3-part series, Sara Gianella Weibel, MD, on behalf of Infectious Disease Advisor, talks with Jeff Taylor, community activist and long-term HIV survivor, about ethical concerns and practical barriers in end-of-life research and how the HIV community will embrace this type of research.

Published
21 June 2017
From
Infectious Disease Advisor
Last Gift Study: End-of-Life HIV Research

Few opportunities currently exist for terminally ill people to participate in HIV research as a result of various cultural taboos and ethical concerns, such as exploitation, vulnerability, and coercion. However, when faced with their approaching death, some individuals may be willing to participate in research that offers no hope for their condition to leave a final gift to their community.

Published
21 June 2017
From
Infectious Disease Advisor
Medicine information leaflets 'too scary', say experts

A more balanced view of the benefits and potential side effects is being called for in a report.

Published
20 June 2017
From
BBC Health
Understanding HIV's persistence

A new study, published in the Journal of Clinical Investigation, led by Mathias Lichterfeld, MD, PhD, and Guinevere Lee, PhD, from the Brigham and Women's Hospital Infectious Disease Division sheds new light on the mechanism underlying the persistence of HIV-1 infected cells despite antiviral treatment. "Our research points to a driving force that stabilizes the pool of HIV-infected cells in the host, which can persist lifelong despite very effective antiretroviral therapy," said Lichterfeld.

Published
20 June 2017
From
EurekAlert (press release)
Top HIV expert is not donating to crowdfunding HIV vaccine campaign, says it's "Fake News"

Dr. Carl W. Dieffenbach, head of the AIDS division of the US National Institutes of Health, has denounced an HIV vaccine crowdfunding campaign involving prominent stars. The major fundraising #ENDHIV campaign which features SIA, the campaign’s ambassador. Other celebrities include Zoe Saldana and Julianne Moore. Dr Dieffenbach's assessment is not pointed at the celebrities nor the organisation behind the campaign. It’s about the research of scientist, Dr. Paul, whom Dieffenbach asserts “is wrong” in his direction towards discovering the vaccine or cure promoted by the video and the campaign’s website www.endhiv.com. Yet, the #ENDHIV video calls Dr. Paul’s work “a promising new AIDS cure.”

Published
17 June 2017
From
imstilljosh
HIV drug resistance testing not a priority for resource-limited settings, trial finds

Resistance testing is unlikely to improve the effectiveness of second-line HIV treatment in resource-limited settings and the introduction of routine HIV drug resistance testing is

Published
14 June 2017
By
Keith Alcorn
SA's new HIV challenge: patients who believe they've been healed

On the eve of South Africa’s national AIDS conference taking place in Durban this week, it has emerged that people are defaulting on their ARVs – often under the impression that they have been healed. According to health workers Health-e News spoke to, the issue relates to the “undetectable viral load” diagnosis patients receive when their antiretroviral therapy starts working and causes the amount of virus in their blood to drop to an extremely low level.

Published
13 June 2017
From
Citizen
Study: 1 in 3 Patients Starts HIV Treatment Late in 10 Countries

A large team of international researchers has found 30 percent of HIV positive individuals in nearly a dozen countries delay starting life-saving drugs. A study spearheaded by the U.S. Centers for Disease Control and Prevention looked at the prevalence of HIV in Haiti, Vietnam, Nigeria, Namibia, Swaziland, Zimbabwe, Mozambique, Tanzania, Uganda and Zambia.

Published
09 June 2017
From
Voice of America
Meds May Impact Prenatal Screening in HIV+ Patients

Pregnant women with HIV taking integrase inhibitors at the time of their non-invasive prenatal screening test had a lower mean fetal fraction than those who were not taking the medication, a small study found here.

Published
08 June 2017
From
MedPage Today HIV/AIDS

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.